The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer
This trial is active, not recruiting.
|Phase||phase 1/phase 2|
|Sponsor||AHS Cancer Control Alberta|
|Start date||April 2005|
|End date||March 2017|
|Trial size||60 participants|
|Trial identifier||NCT00126802, GU-06-0052/ethics 21781|
Helical tomotherapy is being used to treat the prostate gland, local rates of spread and regional lymph nodes whilst sparing gross structures. The radiation to the gross disease in the prostate is hypofractionated and dose escalated. Magnetic resonance spectroscopic imaging (MRSI) is incorporated into pre- and post-treatment evaluation.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
time frame: 5 weeks
prostate-specific antigen (PSA) and MRSI disease control
time frame: 3 years
Male participants up to 75 years old.
Inclusion Criteria: - High risk localized prostate cancer Exclusion Criteria: - Low/intermediate risk, metastatic cancer - Patient refusal
|Official title||The Role of Tomotherapy (Dynamic IMRT and Megavoltage CT Scanning) in Hypofractionated/Dose Escalated Conformal Radiation Treatment Using Magnetic Resonance Spectroscopy (MRS) Scans to Predict and Document the Pattern of Local Failure for High Risk Prostate Cancer|
|Principal investigator||Robert Pearcey, MD|
Call for more information